Brief follow-up to my last comment. I did a quick review of the '413 patent prosecution history. There were no "prior art" rejections - possibly meaning that Heplisav MAY not infringe any existing patents (GSK? Pfizer?). Also, the '413 patent received 402 days of patent term adjustment (PTA) - and likely should receive additional patent term extension (PTE) up to 5 years for undergoing regulatory review at FDA. That's over 6 years additional patent term. A good thing.
Agreed, very nice find moose_catcher. Even better is the realization that this is just the most recent one of a total of 26 listed "immunomodulatory patents" with Dynavax as the assignee. All 26 of these patents should help DVAX if any IP licensing issues arise. Both parties will likely conclude that cross-licensing is in everyone's best interest (and forgo expensive litigation).